Inventor · disambiguated record
Joanne L. Viney
Also filed as: VINEY JOANNE L · VINEY JOANNE LOUISE
21 granted patents·24 pending applications·125 citations·filing 2003–2025
94Inventor score
Top patents by PatentIndex Score
45 records- 0197US10676516B2Targeted immunotolerancePANDION THERAPEUTICS INC·Filed 2018·Granted Jun 9, 2020·26 cites·29 claims
- 0297US10174091B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·31 cites·25 claims
- 0397US10174092B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·28 cites·25 claims
- 0494US11091527B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·5 cites·2 claims
- 0593US11091526B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·4 cites·2 claims
- 0693US10946068B2IL-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Granted Mar 16, 2021·9 cites·27 claims
- 0791US11466068B2Targeted immunotolerancePANDION OPERATIONS INC·Filed 2020·Granted Oct 11, 2022·2 cites·11 claims
- 0891US10961310B2Targeted immunotolerancePANDION OPERATIONS INC·Filed 2018·Granted Mar 30, 2021·6 cites·7 claims
- 0989US2024239858A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1089US2024247039A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1183US10357561B2BTNL9 proteins, nucleic acids, and antibodies and uses thereofAMGEN INC·Filed 2015·Granted Jul 23, 2019·4 cites·9 claims
- 1281US11459370B2BTNL3 proteins, nucleic acids and antibodies and uses thereofAMGEN INC·Filed 2019·Granted Oct 4, 2022·1 cites·1 claims
- 1380US11965008B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 23, 2024·0 cites·19 claims
- 1480US8609655B2Calcimimetic compound for use in the treatment of epithelial injuryGEIBEL JOHN PETER·Filed 2009·Granted Dec 17, 2013·2 cites·5 claims
- 1579US11945852B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 2, 2024·0 cites·22 claims
- 1677US11981715B2Tissue targeted immunotolerance with a CD39 effectorPANDION OPERATIONS INC·Filed 2021·Granted May 14, 2024·1 cites·7 claims
- 1777US2025361283A1Btnl3 proteins, nucleic acids and antibodies and uses thereofAMGEN INC·Filed 2025·Application pending·0 cites
- 1877US2023192802A1Btnl3 proteins, nucleic acids and antibodies and uses thereofAMGEN INC·Filed 2022·Application pending·0 cites
- 1974US8674078B2Methods of using BTL-II proteinsBAUM PETER R·Filed 2012·Granted Mar 18, 2014·2 cites·20 claims
- 2074US2019169255A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2173US7244822B2BTL-II proteinsIMMUNEX CORP·Filed 2003·Granted Jul 17, 2007·4 cites·26 claims
- 2270US2025002582A1Targeted immunotolerance with a pd-1 agonistPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2370US2019169254A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2469USRE50550EIL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2022·Granted Aug 26, 2025·0 cites·27 claims
- 2568US2024025995A1Dual targeted immune regulating compositionsSEISMIC THERAPEUTIC INC·Filed 2023·Application pending·0 cites
- 2667US2024342260A1Tissue-directed antibodies and methods of using the sameZAG BIO INC·Filed 2024·Application pending·0 cites
- 2766US2023272072A1Dual targeted immune regulating compositionsSEISMIC THERAPEUTIC INC·Filed 2022·Application pending·0 cites
- 2863US7709618B2BTL-II nucleic acidsIMMUNEX CORP·Filed 2007·Granted May 4, 2010·0 cites·40 claims
- 2962US11779632B2IL-2 muteins and uses thereofPANDION OPERATION INC·Filed 2021·Granted Oct 10, 2023·0 cites·20 claims
- 3062US2022002409A1Targeted ImmunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3158US2015166630A1Btnl3 proteins, nucleic acids, and antibodies and uses thereofAMGEN INC·Filed 2013·Application pending·0 cites
- 3258US2024228619A9Pancreas targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3357US2025320292A1Kidney-glomerular targeted immunotherapyPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3457US2025019431A1Kidney targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3554US2021206856A1Targeted immunotolerance with a pd-1 agonistPANDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3652US2024301064A1Pd-1 antibodies, polypeptides and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3751US2024010722A1Madcam targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3851US2024262905A1Skin targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3951US2024052034A1Multi-paratopic anti-pd-1 antibodies and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4049US2022041713A1Targeted immunotolerancePANDION OPERATIONS INC·Filed 2019·Application pending·0 cites
- 4148US8173603B2Methods of using BTL-II proteinsBAUM PETER R·Filed 2010·Granted May 8, 2012·0 cites·11 claims
- 4247US2023235004A1Tissue targeted immunotolerance with pd-1 agonists or il-2 muteinsPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4346US11739146B2MAdCAM targeted immunotolerancePANDION OPERATIONS INC·Filed 2020·Granted Aug 29, 2023·0 cites·9 claims
- 4445US2021277085A1Targeted immunotolerancePANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4544US2013101590A1Btnl9 proteins, nucleic acids, and antibodies and uses thereofARNETT HEATHER A·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →